Home Cart Sign in  
Chemical Structure| 892711-75-0 Chemical Structure| 892711-75-0

Structure of CDN1163
CAS No.: 892711-75-0

Chemical Structure| 892711-75-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

CDN1163 is an allosteric sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) activator that improves Ca2+ homeostasis. CDN1163 attenuates diabetes and metabolic disorders.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of CDN1163

CAS No. :892711-75-0
Formula : C20H20N2O2
M.W : 320.39
SMILES Code : O=C(NC1=C2N=C(C)C=CC2=CC=C1)C3=CC=C(OC(C)C)C=C3
MDL No. :MFCD07177494
InChI Key :GVGVYDCVFBGALZ-UHFFFAOYSA-N
Pubchem ID :16016585

Safety of CDN1163

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
H1395 cells 10 μM 24 hours CDN1163 attenuated mitochondrial dysfunction in IAV-infected H1395 cells. PMC8139658
Mouse renal tubular epithelial cells (mRTECs) 10 μM 1 h pretreatment followed by 24 h treatment CDN1163 restored Cd2+-induced reduction in ER Ca2+ content and decreased the expression of ER stress markers BiP, PDI, and apoptosis marker cleaved caspase-3 PMC10053525
HT22 cells 10 μM 10 min CDN1163 enhanced cytoplasmic Ca2+ clearance of SERCA2 mutants and attenuated hypo-glutamate-induced excitotoxicity PMC9065279
Reconstituted proteoliposomes (containing SERCA1a isoform) 10μM 15 minutes Confirmed direct interaction with SERCA protein showing ~26% increase in charge displacement PMC8571031
Rabbit skeletal muscle SR vesicles 10μM 15 minutes CDN1163 significantly enhanced ATP-dependent Ca2+ translocation by SERCA with ~30% increase in charge displacement PMC8571031
Jurkat T lymphocytes 10 µM 20 min Short-term exposure to CDN1163 significantly increased Ca2+ release responses induced by low-dose tBHQ, indicating enhanced Ca2+ release from the SERCA 3-regulated Ca2+ pool. PMC11593871
HT22 mouse hippocampal neurons 1 µM 24 hours CDN1163 significantly alleviated heat stress-induced calcium imbalance, reduced cytoplasmic Ca2+ levels and elevated ER Ca2+ levels, inhibited p-PERK and p-eIF2α protein expression, effectively attenuating endoplasmic reticulum stress and apoptosis. PMC11167007
H9c2 cells 10 μM 24 hours CDN1163 markedly abolished glucose-stimulated NFATc nuclear translocation, reduced resistin and nuclear NFATc expression, and increased AMPKα phosphorylation. PMC6199245
HEK cells 10 μM 2-hour pretreatment followed by 16-hour exposure to H2O2 To evaluate the rescue effect of CDN1163 on ER stress-induced cell death; CDN1163 significantly attenuated H2O2-stimulated cell death PMC4777852
Jurkat T lymphocytes 25 µM 30 min Short-term exposure to CDN1163 significantly inhibited Ca2+ uptake, suggesting SERCA function was suppressed. PMC11593871
H2K-mdx myotubes 100 μM 30 minutes CDN1163 significantly reduced cytosolic Ca2+ levels in H2K-mdx myotubes PMC8170845
Lymphatic muscle cells (LMCs) 5 μM 48 hours To evaluate the effect of CDN1163 on SERCA activity in insulin-resistant LMCs. Results showed that CDN1163 partially restored the contractile frequency of lymphatic vessels. PMC7378550
Jurkat T lymphocytes 10 µM 72 h Long-term exposure to CDN1163 increased Ca2+ store levels in the SERCA 2b pool but decreased store levels in the SERCA 3-regulated pool. PMC11593871

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 mice Heat stress-induced cognitive impairment model Intraperitoneal injection 20 mg/kg Once daily for 7 days CDN1163 upregulated SERCA expression, restored Ca2+ homeostasis, improved learning and memory abilities, and alleviated hippocampal neuronal damage and endoplasmic reticulum stress-mediated apoptosis. PMC11167007
Mice CuZnSOD deficient Mice model Intraperitoneal injection 50 mg/kg Three times per week for 7 weeks CDN1163 completely restored SERCA activity and reversed the 23% reduction in gastrocnemius mass and 22% reduction in specific force in untreated Sod1-/- versus wild type mice. These changes were accompanied by restoration of autophagy protein markers to the levels found in wild-type mice. CDN1163 also reversed the increase in mitochondrial ROS generation and oxidative damage in muscle tissue from Sod1-/- mice. PMC6174848
Mice Wild-type (WT) and melanocortin-4 receptor knockout (Mc4r−/−) mice Injections 50 mg/kg Once every 2 weeks for 8 weeks (four total doses); or three times per week for 8 weeks (24 total doses) Studied the effects of CDN1163 on diet-induced steatohepatitis, showing that CDN1163 improved liver fibrosis and inflammation, restored glucose tolerance and insulin sensitivity, increased antioxidant enzyme expression, and decreased oxidative stress and ER stress gene expression. PMC11179628
Mice Diabetic Mice model (db/db mice) Intraperitoneal injection 100 mg/kg 5 consecutive days CDN1163 improved glucose tolerance, hepatosteatosis, skeletal muscle function, and insulin resistance in db/db mice. PMC9099866
Wistar rats Hindlimb unloading/suspension model Intraperitoneal injection 50 mg/kg Once daily for 7 days Treatment with SERCA activator CDN1163 during 7 days of unloading prevented an increase in soleus fatigue, the decrease of slow-type myosin, mitochondrial markers, and markers of calcium homeostasis but had no effect on muscle atrophy. PMC10526198
C57BL/6J mice Aged mice Intra-peritoneal injection 50 mg/kg Three times per week for 10 months CDN1163 treatment via diet and injection prevented age-related muscle atrophy and weakness, restored SERCA ATPase activity, and improved mitochondrial function. PMC7792969
Ob/ob mice (obese/diabetic model) Insulin resistance and type 2 diabetes model Intraperitoneal injection 50 mg/kg Once daily for 5 consecutive days To evaluate the effects of CDN1163 on blood glucose and metabolic parameters; CDN1163 significantly reduced fasting blood glucose, improved glucose tolerance, ameliorated hepatic steatosis, increased energy expenditure, and upregulated UCP1 and UCP3 expression in brown adipose tissue. Effects persisted for >6 weeks post-treatment. PMC4777852
Mdx mice Duchenne muscular dystrophy model Intraperitoneal injection 40 mg/kg Three times per week for 7 weeks CDN1163 ameliorated dystrophic phenotypes in mdx mice, including reduced muscle degeneration and fibrosis, enhanced muscle strength, and restored mitochondrial function PMC8170845
Ob/ob mice Diabetic mice model Intraperitoneal injection 50 mg/kg 3× /week for 30 days CDN1163 treatment significantly decreased resistin and nuclear NFATc protein expression and increased AMPKα activity/phosphorylation. PMC6199245

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.12mL

0.62mL

0.31mL

15.61mL

3.12mL

1.56mL

31.21mL

6.24mL

3.12mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories